Renal Cell Carcinoma Pipeline Insights, 2021 Report – ResearchAndMarkets.com

Renal Cell Carcinoma Pipeline Insights, 2021 Report – ResearchAndMarkets.com




Renal Cell Carcinoma Pipeline Insights, 2021 Report – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Renal Cell Carcinoma – Pipeline Insight, 202” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “Renal Cell Carcinoma – Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Renal Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence R&D. Renal Cell Carcinoma The therapies under development are focused on novel approaches to treat/improve Renal Cell Carcinoma.

RENAL CELL CARCINOMA Emerging Drugs Chapters

This segment of the Renal Cell Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Renal Cell Carcinoma Emerging Drugs

CM082: Betta Pharmaceuticals

CM082 series have the similar skeletal structures to Icotinib Hydrochloride, as the multi-target RTK (receptor tyrosine kinase) inhibitor, mainly targeting at VEGFR and PDGFR. The drug is being evaluated in phase III stage of development for the treatment of Renal cell carcinoma.

TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

TQB 2450 (formerly APL 502 and CBT 502) is a humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting the programmed cell death-1 ligand-1. Phase III clinical trials are being evaluated by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. for TQB 2450 for the treatment of renal cell carcinoma.

IPI-549: Infinity Pharmaceuticals

IPI-549 is an oral immuno-oncology candidate which has been designed to preferentially inhibit PI3K-gamma. The drug is being studied in phase II stage of development for the treatment of renal cell carcinoma.

CMN-001: ColImmune

Dendritic cells have been used by colimmune for the treatment of renal failure. CMN001 is a dendritic cell vaccine for renal cell carcinoma. The drug is being evaluated in phase II stage of development for the treatment of renal cell carcinoma.

Renal Cell Carcinoma: Therapeutic Assessment

This segment of the report provides insights about the different RENAL CELL CARCINOMA drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Renal Cell Carcinoma

There are approx. 30+ key companies which are developing the therapies for RENAL CELL CARCINOMA. The companies which have their Renal Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Betta Pharmaceuticals.

Phases

This report covers around 30+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration

Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Subcutaneous
  • Intravenous
  • Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

  • Bispecific Antibody
  • Peptides
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Renal Cell Carcinoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Renal Cell Carcinoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Renal Cell Carcinoma drugs.

RENAL CELL CARCINOMA Report Insights

  • Renal Cell Carcinoma Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

RENAL CELL CARCINOMA Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered

  • How many companies are developing Renal Cell Carcinoma drugs?
  • How many Renal Cell Carcinoma drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Renal Cell Carcinoma?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Renal Cell Carcinoma therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Renal Cell Carcinoma and their status?
  • What are the key designations that have been granted to the emerging drugs?

Companies Mentioned

  • Amgen
  • Aravivie Inc
  • AstraZeneca
  • Aveao pharmaceuticals
  • Bayer Healthcare
  • Betta Pharmaceuticals
  • Bristol-Myers Squibb
  • Cemiplimab
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • ColImmune
  • GlaxoSmithKline
  • Hoffman La Roche
  • Incyte Corporation
  • Infinity Pharmaceuticals
  • Ipsen
  • Merck Sharp & Dohme Corp.
  • Novartis
  • Pfizer
  • Regeneron Pharmaceuticals
  • X4 pharmaceuticals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/m20tja

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900